XCNQ
ENBI
Market cap974kUSD
, Last price
CAD
Name
Entheon Biomedical Corp
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
37.34%
Rev. gr., 5y
%
Revenues
0
Net income
-324k
L+1.89%
CFO
-315k
L-11.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Entheon Biomedical Corp. functions as a biotechnology firm focused on the research and development of novel pharmaceuticals. The company is actively involved in pioneering and introducing to market psychedelic therapeutic products, specifically those derived from N,N-dimethyltryptamine (DMT), with the aim of combating addiction and various substance use disorders. Its services are provided to medical doctors, healthcare facilities, and accredited psychiatrists across Canada, the United States, and the European Union. Entheon Biomedical Corp.'s primary operations are based in Vancouver, Canada.
Key people
Soo-whan Kim
Interim Chief Financial Officer · since 2023
Timothy Ko
President, Chief Executive Officer, Director · since 2020
Christopher Gondi
Independent Director · since 2020
Legal address
10TH FLOOR – 595 HOWE STREET
VANCOUVER, BC V6C 2T5
CA
VANCOUVER, BC V6C 2T5
CA
Headquarters
720-999 WEST BROADWAY
VANCOUVER, BC V5Z 1K5
CA
VANCOUVER, BC V5Z 1K5
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑11 | 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2020‑03 | 2019‑11 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||